Genedrive has successfully completed an oversubscribed US$10 million equity fundraise
Genedrive plc has completed an equity fundraising to support the rapid development of the Genedrive® SARS-CoV-2 assays, fund the scale-up of the Genedrive-96-SARS-CoV-2 test including build-up of inventory for an initial period, fund product development, commercialization and general corporate purposes.
Genedrive is a molecular diagnostics company developing and commercializing a low-cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company is passionate about the opportunity to not only build a sustainable business around molecular diagnostics, but to play an important role in the diagnostic and treatment challenges presented by global health issues.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Genedrive plc on its oversubscribed equity fundraising.
Talk to the deal team
PartnerLondon, United Kingdom
Alexandria Pankkiiriliike Oyj has raised US$9.7m in the course of its IPO on NASDAQ First North Finland
Alexandria Pankkiiriliike Oyj (Alexandria) has raised US$9.7 million in the course of its IPO.Learn more
Gilde Healthcare has invested in Tandarts Today
Gilde Healthcare has invested in Tandarts Today, a fast-growing dental chain in the Netherlands. The investment will allow Tandarts Today to accelerate its buy-and-build strategy and become a leading dental chain in the Netherlands. Financial details have not been disclosed.Learn more
Avantium has raised US$33.6m via an accelerated bookbuild offering
Avantium N.V. has raised US$33.6 million through an accelerated bookbuild offering of 5,206,589 new ordinary shares, representing approximately 19.99% of the company’s issued share capital. The shares have been placed at a price of US$6.42 (€5.35) per new ordinary share.Learn more